1Master of Clinical Pharmacy Program, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia
2Department of Pharmacology and Clinical Pharmacy, School of Pharmaceutical Sciences, Padang, Indonesia
3Department of Pharmacy Practice, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia
4Department of Internal Medicine, Surabaya Hajj General Hospital, Surabaya, Indonesia
5Department of Hospital Pharmacy, Surabaya Hajj General Hospital, Surabaya, Indonesia
*Corresponding Author E-mail: suharjono@ff.unair.ac.id
Online published on 27 February, 2023.
Inflammation is the underlying cause of several comorbid diseases, including macrovascular complications that cause the highest mortality in diabetes patients. One of the pro-inflammatory cytokines used to assess inflammatory conditions in diabetes and its complications is IL-6. This study intends to analyze the effect of atorvastatin administration on lipid profile and inflammatory markers after 30 days and the correlation between lipid profile and IL-6. An observational prospective cohort study was conducted from November 2017 to January 2018 and approved by the ethical committee of General Hajj Hospital, Surabaya. Nineteen patients who met the inclusion criteria and signed the informed consent enrolled in this study. The measurement of lipid profile and IL-6 level were done twice, before and after 30 days of atorvastatin therapy. After atorvastatin administration, there was a 40.55% decrease in LDL level, a 15.34% decrease in TG level, a 30.70% decrease in total cholesterol level, which was statistically significant (p<0.05), and a 6.06% increase in HDL level. There was a 5.76% decrease in the IL-6 level (p>0.05). In conclusion, atorvastatin administration can improve lipid profile in diabetes patients with dyslipidemia. There was a decrease in IL-6 but not statistically different. From statistical analysis, there is no correlation found between lipid profile and IL-6
Atorvastatin, Diabetes, Dyslipidemia, IL-6, Lipid profile
